Your browser doesn't support javascript.
loading
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Virgolini, Irene; Bahri, Shadfar; Kjaer, Andreas; Grønbæk, Henning; Iversen, Peter; Carlsen, Esben A; Loft, Mathias; Knigge, Ulrich; Maffey-Steffan, Johanna; Powell, Christine; Miller, Colin G; Rohban, Thomas; McEwan, Sandy; Czernin, Johannes.
Afiliación
  • Virgolini I; Department of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria; irene.virgolini@i-med.ac.at.
  • Bahri S; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Kjaer A; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Grønbæk H; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Iversen P; Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
  • Carlsen EA; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Loft M; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Knigge U; Department of Endocrinology PE and Department of Surgery C, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Maffey-Steffan J; Department of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria.
  • Powell C; Ipsen Bioscience, Cambridge, Massachusetts.
  • Miller CG; Bracken Group for Ipsen Bioscience, Newtown, Pennsylvania; and.
  • Rohban T; Partner 4 Health for Ipsen Bioscience, Paris, France.
  • McEwan S; Ipsen Bioscience, Cambridge, Massachusetts.
  • Czernin J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
J Nucl Med ; 63(3): 376-383, 2022 03.
Article en En | MEDLINE | ID: mdl-34215673
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organometálicos / Tumores Neuroendocrinos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Nucl Med Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organometálicos / Tumores Neuroendocrinos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Nucl Med Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos